File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/00029330-200810010-00016
- Scopus: eid_2-s2.0-54349118506
- PMID: 19080128
- WOS: WOS:000261200500016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: A meta-analysis
Title | Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: A meta-analysis |
---|---|
Authors | |
Keywords | Meta-analysis Head and neck Neoplasm Neoadjuvant chemotherapy |
Issue Date | 2008 |
Publisher | Chinese Medical Association. The Journal's web site is located at http://www.cmj.org/ |
Citation | Chinese Medical Journal, 2008, v. 121, n. 19, p. 1939-1944 How to Cite? |
Abstract | Background: The benefit of neoadjuvant chemotherapy in the management of head and neck squamous cell carcinomas (HNSCC) still remains controversial. The aim of this meta-analysis is to evaluate the role of the neoadjuvant chemotherapy with the cisplatin and fluororacil (PF) regimen in enhancing the overall survival of and decreasing locoregional relapse and distant metastasis in HNSCC patients. Methods: Medline and manual searches were performed to identify all published randomized controlled trials (RCTs) investigating the efficacy of the neoadjuvant chemotherapy with the PF regimen. Outcomes assessed by meta-analysis included locoregional relapse, distant metastasis, and overall survival. The odds ratio was the principle measurement of effect, which was calculated as the treatment group (chemotherapy plus locoregional treatment) versus the control group (locoregional treatment alone) and was presented as a point estimate with 95% confidence intervals (CI). Results: Eight RCTs were adopted for analysis. The meta-analysis showed that the odds ratio for the locoregional relapse was 0.92 (0.70-1.22, 95%Cl), which was not statistically significant. The odds ratios for distant metastasis and overall survival were 0.47 (0.33-0.68, 95% Cl) and 1.28 (1.01-1.62, 95% Cl) respectively, which were both statistically significant. Conclusions: Neoadjuvant chemotherapy with the PF regimen in HNSCC patients has no effect on locoregional relapse. However, it shows a small but significant benefit in reducing distant metastasis and improving the overall survival. |
Persistent Identifier | http://hdl.handle.net/10722/199967 |
ISSN | 2021 Impact Factor: 6.133 2020 SCImago Journal Rankings: 0.537 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Su, Yuxiong | - |
dc.contributor.author | Zheng, Jiawei | - |
dc.contributor.author | Zheng, Guangsen | - |
dc.contributor.author | Liao, Guiqing | - |
dc.contributor.author | Zhang, Zhiyuan | - |
dc.date.accessioned | 2014-07-26T23:10:58Z | - |
dc.date.available | 2014-07-26T23:10:58Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Chinese Medical Journal, 2008, v. 121, n. 19, p. 1939-1944 | - |
dc.identifier.issn | 0366-6999 | - |
dc.identifier.uri | http://hdl.handle.net/10722/199967 | - |
dc.description.abstract | Background: The benefit of neoadjuvant chemotherapy in the management of head and neck squamous cell carcinomas (HNSCC) still remains controversial. The aim of this meta-analysis is to evaluate the role of the neoadjuvant chemotherapy with the cisplatin and fluororacil (PF) regimen in enhancing the overall survival of and decreasing locoregional relapse and distant metastasis in HNSCC patients. Methods: Medline and manual searches were performed to identify all published randomized controlled trials (RCTs) investigating the efficacy of the neoadjuvant chemotherapy with the PF regimen. Outcomes assessed by meta-analysis included locoregional relapse, distant metastasis, and overall survival. The odds ratio was the principle measurement of effect, which was calculated as the treatment group (chemotherapy plus locoregional treatment) versus the control group (locoregional treatment alone) and was presented as a point estimate with 95% confidence intervals (CI). Results: Eight RCTs were adopted for analysis. The meta-analysis showed that the odds ratio for the locoregional relapse was 0.92 (0.70-1.22, 95%Cl), which was not statistically significant. The odds ratios for distant metastasis and overall survival were 0.47 (0.33-0.68, 95% Cl) and 1.28 (1.01-1.62, 95% Cl) respectively, which were both statistically significant. Conclusions: Neoadjuvant chemotherapy with the PF regimen in HNSCC patients has no effect on locoregional relapse. However, it shows a small but significant benefit in reducing distant metastasis and improving the overall survival. | - |
dc.language | eng | - |
dc.publisher | Chinese Medical Association. The Journal's web site is located at http://www.cmj.org/ | - |
dc.relation.ispartof | Chinese Medical Journal | - |
dc.subject | Meta-analysis | - |
dc.subject | Head and neck | - |
dc.subject | Neoplasm | - |
dc.subject | Neoadjuvant chemotherapy | - |
dc.title | Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: A meta-analysis | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1097/00029330-200810010-00016 | - |
dc.identifier.pmid | 19080128 | - |
dc.identifier.scopus | eid_2-s2.0-54349118506 | - |
dc.identifier.volume | 121 | - |
dc.identifier.issue | 19 | - |
dc.identifier.spage | 1939 | - |
dc.identifier.epage | 1944 | - |
dc.identifier.isi | WOS:000261200500016 | - |
dc.publisher.place | China | - |
dc.identifier.issnl | 0366-6999 | - |